192,373 Shares in DexCom, Inc. $DXCM Purchased by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 192,373 shares of the medical device company’s stock, valued at approximately $12,081,000.

Other institutional investors also recently bought and sold shares of the company. Reflection Asset Management bought a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the first quarter valued at about $25,000. CVA Family Office LLC lifted its holdings in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth $32,000. Finally, ORG Partners LLC grew its position in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 71,750 shares of company stock valued at $5,163,241. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on DXCM. Citigroup reissued a “buy” rating and issued a $84.00 target price (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 price target on shares of DexCom in a report on Monday, June 8th. Stifel Nicolaus set a $90.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, June 5th. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 8th. Finally, William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.36.

DexCom Stock Down 1.7%

NASDAQ:DXCM opened at $76.65 on Friday. The company’s fifty day moving average price is $71.16 and its 200-day moving average price is $68.73. The firm has a market capitalization of $29.58 billion, a P/E ratio of 32.76, a PEG ratio of 1.28 and a beta of 1.45. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.